Black box warnings for JAK inhibitors arise from rheumatoid arthritis studies, leading one expert to question the risk-benefit relevance to dermatologic diseases, particularly in younger patients.
Citing a lack of efficacy data, the FDA has declined to approve omecamtiv mecarbil (Cytokinetics) for treatment of adults with chronic heart failure with reduced ejection fraction.
New guidelines for de-labeling of penicillin allergy urge allergists to skip skin testing and recommend direct oral challenge to low-risk patients. Validated risk tools can help.